

Att-20
#6

FORM PTO-149 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-3	APPLICATION SERIAL NO. 08/462,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Ln	4,141,973	02-1979	Balazs	—	—	
Ln	4,582,865	04-1986	Balazs et al.	—	—	
Ln	4,636,524	01-1987	Balazs et al.	—	—	
Ln	4,711,780	12-1987	Fahim	—	—	
Ln	4,725,585	02-1988	Wenge et al.	—	—	
Ln	4,736,024	04-1988	Della Valle et al.	—	—	
Ln	4,755,544	07-1988	Makino et al.	—	—	
Ln	4,795,741	01-1989	Leshchiner et al.	—	—	
Ln	4,801,619	01-1989	Lindblad	—	—	
Ln	4,808,576	02-1989	Schultz et al.	—	—	
Ln	4,814,176	03-1989	Makino et al.	—	—	
Ln	4,840,941	06-1989	Ueno et al.	—	—	
Ln	4,851,521	07-1989	della Valle et al.	—	—	
Ln	4,937,254	06-1990	Sheffield et al.	—	—	
Ln	4,957,744	09-1990	della Valle et al.	—	—	
Ln	4,965,353	10-1990	della Valle et al.	—	—	
Ln	4,970,298	11-1990	Silver et al.	—	—	
	07/338,106	04-1989	Falk			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
Ln	1,205,031	05-1986	Canada	—	—		
Ln	1,240,929	08-1988	Canada	—	—		
Ln							
Ln	0 138 572	04-1985	Europe	—	—		
Ln	0 179 442	04-1986	Europe	—	—		
Ln	0 197 718	10-1986	Europe	—	—		
Ln	0 208 623	01-1987	Europe	—	—		
Ln	0 216 453	04-1987	Europe	—	—		
Ln	0 224 987	06-1987	Europe	—	—		

*This was taken from Application Serial No. 07/675,908

FORM PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(0)-3	APPLICATION SERIAL NO. 08/462,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
67	0 240 098	10-1987	Europe				
67	0 265 116	04-1988	Europe				
67	0 270 317	06-1988	Europe				
67	0 285 357	10-1988	Europe				
67	0 287 210	10-1988	Europe				
67	0 295 092	12-1988	Europe				
67	0 296 740	12-1988	Europe				
67							
	63/045223		Japan - English translation will follow				
67	61000017	01-1986	Japan - English translation will follow				
67	WO 88/07060	09-1988	PCT				
67	WO 89/07932	09-1989	PCT				
	WO 91/04058	04-1991	Int'l Search Report				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

67	Sandra Blakeslee, "Solid cores of tumors keeping out best drugs", July 8, 1989 edition of the Globe and Mail, Toronto, Ontario, Page D4.
67	Pam Harrison, "Toxic drug tamed but still potent" <u>Ontario Medicine</u> , Volume 8, No. 16 dated August 21, 1989, Page 1.
67	<u>The Merck Index</u> Eleventh Edition, Centennial Edition, Hyaluronic Acid formulation, Pages 751 and 752.
67	Alan R. Liss, Inc., Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists, <u>Immunity to Cancer II</u> (will follow)
67	Goodwin, J.S. Prostaglandin E and Cancer Growth Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, <u>Augmentive Agents in Cancer Therapy</u> , Raven Press, New York, (1981) (will follow)
67	Dr. Samuel Asculai, " <u>Inactivation of Herpes Simplex Viruses by Nonionic Surfactants</u> ", <u>Antimicrobial Agents and Chemotherapy</u> , April 1978, pp. 686-690. (will follow)

EXAMINER G. Kelly	DATE CONSIDERED 6/6/96
----------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



CITATION OF PRIOR ART

Sheet 1 of 6

FORM 1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(0)-3	APPLICATION SERIAL NO. 08/462,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
U	2,583,096	01 1952	Hadidian et al			
U	3,436,454	04-1969	Nouvel			
U	3,887,703	06-1975	Manoussos et al			
U	4,272,522	06-1981	Balazs			
U	4,716,224	12-1987	Sakurai et al.			
U	4,853,226	08-1989	Machida et al.			
U	4,946,870	08-1990	Partain, III. et al.			
FOREIGN PATENT DOCUMENTS				Class	Sub-Class	Translation YES NO
	Document No.	Date	Country	Class	Class	
U	B-72117/87	12-1987	Australia			
U	B-17459/88	12-1988	Australia			
U	30806/84	07-1984	Australia			
U	0,378,852	12-1989	Europe			
U	1,283,892	08-1972	Great Britain			
U	2,099,826-A	12-1982	Great Britain			
U	A-116678/88 Application	11-1989 Laid-Open-to-Public	Japan			Yes
U	61-233,622	10-1986	Japan			No
U	57-183,707	12-1982	Japan			Yes
U	2,364,373	10-1975	Germany			Yes

*This was taken from Application Serial No. 07/675,908

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(0)-3	APPLICATION SERIAL NO. 08/462,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

4	Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemia. <i>Bulletin of Experimental Biology and Medicine</i> 1967; 64(9): 967-969.
4	Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: <i>Chemistry and Molecular Biology of the Intercellular Matrix. Volumes III.</i> New York: Academic Press, 1970. PP. 1241-1253.
4	Balazs EA, Band P. Hyaluronic acid: Its structure and use. <i>Cosmetics & Toiletries . Polymers in Cosmetics</i> 1984; 99: 65-72.
4	Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. <i>Acta Pharmaceutica Suecica</i> 1985; 22(6): 315-320.
4	Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. <i>Current Eye Research</i> 1987; 6(6): 779-784.
4	Chang S-C. Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit. <i>Dissertation Abstracts International</i> 1988; 49(2): 367-B.

FORM PTO-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(0)-3	APPLICATION SERIAL NO. 08/462,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

6	Cravioto, R.O., et al. Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid From Vitreous Humor in Depressing Blood-Sugar Levels <i>Science</i> (1950); Vol. 111: 520-521
6	Gieldanowski, Jerzy; Skowronska, Jadwiga Studies on immunosuppressive and anti-inflammatory effect of adriamycin. <i>Arch. Immunol. Ther. Exp.</i> (1980); 28 (3): 439-446
6	Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B. Effects of adjuvants to local anaesthetics on their duration. <i>Acta Anaesthesiol. Scand.</i> 1985; 29: 384-388.
6	Hurd ER Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate. <i>Arthritis and Rheumatism</i> (1973 Jan-Feb); 16 (1): 84-88
6	Idson B. Polymers in skin cosmetics. <i>Cosmetics & Toiletries</i> 1988; 103: 63-68.
6	Johansson A, Hassan H, Renck H. Effects of adjuvants to local anaesthetics on their duration. <i>Acta Anaesthesiol. Scand.</i> 1985; 29: 736-738.
6	Kalbhen D.A. The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthritis and its counteraction by a biological GAG-peptide complex (Rumalon®). <i>Z. Rheumatol</i> (1982); 41: 202-211

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-3	APPLICATION SERIAL NO. 08/462,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

4	Katsu M., Abe T., Shimada S. Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence. <i>Nippon Rinsho</i> (1968 Jan); 26(1): 89-95
4	Kreis H, Chkoff N, Droz D, et al. Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients. <i>Transplantation</i> (1984 Feb.); 37(2): 139-145
4	McIlwraith W. Current concepts in equine degenerative joint disease. <i>Journal of the American Veterinary Medical Association</i> 1982; February 1: 239-250.
4	Mizushima, Y. Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future. <i>Nippon Rinsho</i> (Jan. 1986); 26(1): 61-65
4	Nizolek DJH, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A review. <i>The Cornell Veterinarian</i> 1981; 71(4): 355-375.
4	Pigman W, et al. Acide hyaluronique et facteurs de perméabilité tissulaire. <i>Bull. Soc. Chim. Biol.</i> 1963; 5(2-3): 185-202.
6	Pruett RC, Schepens CL, Constable IJ, Swann DA. Hyaluronic acid vitreous substitute. In: <i>Vitreous Surgery and Advances in Fundus Diagnosis and Treatment.</i> Freeman H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55. pp. 433-444.

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-3	APPLICATION SERIAL NO. 08/462,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

41	Reim M, Teping C. Surgical procedures in the treatment of most severe eye burns. <i>Acta Ophthalmologica</i> 1989-Supplementum 192; 67: 47-54.
41	Rydell NW, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. <i>Clinical Orthopaedics and Related Research</i> 1971; 80(October): 25-29.
41	Saba P, Galeone F, Salvadorini F, Guarguaglini M, Ombrato M. Investigation of the antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex. <i>Current Therapeutic Research</i> 1978; 23(4): 455-463.
41	Stegman R, Miller D. Use of sodium hyaluronate in severe penetrating ocular trauma. <i>Acta Ophthalmol.</i> 1986; 18: 9-13.
41	Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E, Baratti C, et al. Prevention of wound dehiscence in severely obese patients with jejuno-ileal by-pass: The role of hyaluronic acid. <i>Pharmatherapeutica</i> 1988; 5(4): 233-239.
41	Sertoli P, Merello A, Parodi M. L'acido ialuronico, per uso topico, nella cura delle ulcere trofo-circolatorie degli arti inferiori. (Comunicazioni). <i>Giornale Italiano di Dermatologia</i> 1970; 45(8): 468-471.
41	Walther, M. The Prevention of Striae Cutis Distansae During Pregnancy. <i>Mineva Gynecologia</i> (1981) Vol. 33: 497-499

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(0)-3	APPLICATION SERIAL NO. 08/462,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

W	Weirich, E.G., Longauer, J.K., Kirkwood, A.H. Dermatopharmacology of salicylic acid. III. Topical contra- inflammatory effect of salicylic acid and other durgs in animal experiments. <i>Dermatologica</i> (1976); 152(2): 87-99
EXAMINER <i>G. Kelly</i>	
DATE CONSIDERED <i>5/6/96</i>	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

Examiner	C. Kehler	Date Considered	6-6-96
----------	-----------	-----------------	--------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*This was taken from Application Serial No. 07/675,908

CITATION OF PRIOR ART

Sheet 1 of 1

FORM PT0-1449 (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-3	APPLICATION SERIAL NO. 08/462,147
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>CW</i>	5,166,331	11-1997	Fidia Della Valle et al			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
<i>CW</i>	14534/88	11-1990	Australia				
<i>CW</i>	15456/88	09-1988	Australia				
<i>CW</i>	17459/88	08-1991	Australia				
<i>CW</i>	29145/89	06-1989	Australia				
	62201825		Japan - English translation				
	62287041		Japan - English translation				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER <i>CW</i>	DATE CONSIDERED 6/6/96
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

*This was taken from Application Serial No. 07/838,674

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

P-0800(0)-3

08/462,147

Information Disclosure
Statement by Applicant

(Use several sheets if necessary)

APPLICANT

Hyal Pharmaceutical Corporation

FILING DATE

June 5, 1995

GROUP

1211

U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
U	4,141,973	2/79	Balazs			
U	4,582,865	4/86	Balazs et al.			
U	4,636,524	1/87	Balazs et al.			
U	4,711,780	12/87	Fahim			
U	4,725,585	2/88	Wenge et al.			
U	4,736,024	4/88	Della Valle et al.			
U	4,755,544	7/88	Makino et al.			
U	4,795,741	1/89	Leschiner et al.			
U	4,801,619	1/89	Lindblad			
U	4,808,576	2/89	Schultz et al.			
U	4,814,176	3/89	Makino et al.			
U	4,840,941	6/89	Ueno et al.			
U	4,851,521	7/89	della Valle et al.			
U	4,937,254	6/90	Sheffield et al.			
U	4,957,744	9/90	della Valle et al.			

FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
U	0 138 572	4/85	Europe			
U	0 179 442	4/86	Europe			
U	0 197 718	10/86	Europe			
U	0 208 623	1/87	Europe			
U	0 216 453	4/87	Europe			
U	0 224 987	6/87	Europe			
U	0 240 098	10/87	Europe			
U	0 265 116	4/88	Europe			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

U	Blakeslee, S., "Solid cores of tumors keeping out best drugs", July 8, 1989 edition of The Globe and Mail, Toronto, Ont., p. D4
U	Harrison, P., "Toxic drug tamed but still potent", Ontario Medicine, Vol. 8, No. 16, 8/21/89, p. 1
U	The Merck Index, Eleventh Edition, Centennial Edition, Hyaluronic Acid formulation, pp. 751-752
U	Braun, DP et al., "Modulation of Immunity in Cancer Patients by Prostaglandin Antagonists", Immunity to Cancer II, 1989, pp 439-448, Alan R. Liss, Inc.,

Examiner

W Keller

Date Considered

6696

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-3	SERIAL NO. 08/462,147
Information Disclosure Statement by Applicant (Use several sheets if necessary)		APPLICANT Hyal Pharmaceutical Corporation	
		FILING DATE June 5, 1995	GROUP 1211

U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
LN	4,965,353	10/90	della Valle et al.			
LN	4,970,298	11/90	Silver et al.			
LN	4,684,627	8/87	LeVeen et al.			
LN	4,303,676	12/81	Balazs			
LN	5,166,331	11/92	della Valle et al.			
LN	5,095,037	3/92	Iwamitsu et al.			
LN	2,583,096	1/52	Hididian et al.			
LN	3,436,454	4/69	Nouvel			
LN	3,887,703	6/75	Manoussos et al.			
LN	4,272,522	6/81	Balazs			
LN	4,716,224	12/87	Sakurai et al.			
LN	4,853,226	8/89	Machida et al.			
LN	4,946,870	8/90	Partain, III, et al.			

FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES, NO
LN	0 270 317	6/88	Europe			
LN	0 285 357	10/88	Europe			
LN	0 287,210	10/88	Europe			
LN	0 295 092	12/88	Europe			
LN	0 296 740	12/88	Europe			
LN	0 312 208		Europe (abstract only)			
LN	0 341 745	5/89	Europe			
LN	0 344 718	4/87	Europe			
LN	0 378,852	7/90	Europe			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

LN		Goodwin, J.S., Prostaglandin E and Cancer Growth: Potential for Immunotherapy with Prostaglandin Synthesis Inhibitors, <u>Augmentive Agents in Cancer Therapy</u> , Raven Press, New York (1981), pp 393-415
LN		
LN		Asculai, Dr. S., "Inactivation of Herpes Simplex Viruses by Nonionic Surfactants", <u>Antimicrobial Agents and Chemotherapy</u> , 4/78, pp. 686-690
LN		Sneider, W.E., Chemical Abstracts, vol. 76, no. 10, "Possible Mechanism for Action of DMSO on Percutaneous absorption, <u>J. Pharm. Pharmacol.</u> , 1971, 23 (Supp)

Examiner <i>C. Kelle</i>	Date Considered <i>6-6-96</i>
--------------------------	-------------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
P-0800(O)-3SERIAL NO.
08/462,147Information Disclosure
Statement by Applicant

(Use several sheets if necessary)

APPLICANT

Hyal Pharmaceutical Corporation

FILING DATE

June 5, 1995

GROUP

1211

U.S. PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
	07/338,106	4/89	Falk (application)			

FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
✓	1,205,031	5/86	Canada			
✓	1,240,929	8/88	Canada			
✓	2,031,880	12/90	Canada			
✓	63/045223	2/88	Japan (w/abstract)			
✓	61000017	1/86	Japan (w/abstract)			
	1287041		Japan (abstract only)			
✓	62201825	1987	Japan (w/abstract)			
✓	62201825	9/87	Japan (translation)			X
✓	62287041	11/89	Japan (translation)			X
✓	A11678:88	5/88	Japan (laid open) (see 1-287041 above)			X
✓	61-233622	10/86	Japan (w/ abstr)			X
✓	57-183707	11/82	Japan (translation) (corrected date)			X

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

✓		International Preliminary Examination Report for PCT/CA90/00306 and attachement substitute claims
✓		Alaverdyan et al., "Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemia".
✓		Bulletin of Experimental Biology & Medicine 1967: 64(9): 967-969
✓		Balazs et al., "The rheological properties and biological function of hyaluronic acid", Chem. and Mol. Biol. of the Intercellular Matrix, Vol. 3, 1970, pp 1241-1253

Examiner

✓ R. L. L.

Date Considered

6/6/96

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. P-0800(O)-3		SERIAL NO 08/462,147	
Information Disclosure Statement by Applicant (Use several sheets if necessary)				APPLICANT Hyal Pharmaceutical Corporation			
				FILING DATE June 5, 1995		GROUP 1211	

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Exmr Initial	Document Number	Date	Country	Class	Sub Class	Translation YES NO
GA	AUB14534/88	11/90	Australia (corrected date)			
GA	AUB17459/88	12/88	Australia	///		
GA	B-72117/87	12/87	Australia	///		
GA	B-17459/88	12/88	Australia	///		
GA	30806/84	7/84	Australia	///		
GA	769,287	3/57	UK	///		
GA	1,283,892	8/72	GB	///		
GA	2,099,826-A	12/82	GB	///		
GA	2364373	10/75	Germany	///		X
GA	WO88/07060	9/88	PCT	///		
GA	WO89/07932	9/89	PCT	///		
GA	WO91/04058	4/91	Intrnar'l Search Report (corresponds to U.S. Appl.)	///		
GA	WO88/07060	9/88	PCT (submitted twice)	///		
GA	WO89/05645	6/89	PCT	///		

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

41		Balez E.A. et al. "Hyaluronic acid: Its structure and use", <u>Cosmetics & Toiletries</u> , <u>Polymers in Cosmetics</u> 1984; 99: 65-72	F
42		Camber O. et al. "Diffusion of some low molecular weight compounds in sodium hyaluronate", <u>Acta Pharmaceutica Suecica</u> 1985; 22(6): 315-320	F
43		Camber O. et al. "Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits", <u>Current Eye Research</u> 1987; 6(6): 779-784	F
44		Chang S-C. "Prodrug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit", <u>Dissertation Abstracts International</u> 1988; 49(2): 367-B	F

Examiner	<i>C. K. K.</i>	Date Considered	<i>6/24/6</i>
----------	-----------------	-----------------	---------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32) Information Disclosure Statement by Applicant (Use several sheets if necessary)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. P-0800(O)-3 APPLICANT Hyal Pharmaceutical Corporation FILING DATE June 5, 1995	SERIAL NO. 08/462,147 GROUP 1211
---	--	--	---

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

Cm		Cravioto R O et al, "Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoïd from Vitreous Humor in Depressing Blood-Sugar Levels <u>Science</u> (1950); Vol. 111: 520-521 F
Cm		Gieldanowski J et al, "Studies on immunosuppressive and anti-inflammatory effects of adriamycin", <u>Arch. Immunol. Ther. Exp.</u> (1980); 28(3): 439-446 F
Cm		Hassan, H.G., et al., "Effects of adjuvants to local anaesthetics on their duration", <u>Acta Anaesthesiol Scand</u> 1985; 29: 384-388 F
Cm		Hurd, E.R., "Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexate", <u>Arthritis and Rheumatism</u> (1973 Jan/Feb); 16(1): 84-88 F
Cm		Idson B, "Polymers in skin cosmetics", <u>Cosmetics & Toiletries</u> 1988; 103: 63-68 F
Cm		Johansson A. et al, "Effects of adjuvants to local anaesthetics on their duration", <u>Acta Anaesthesiol Scand</u> 1985; 29: 736-738 F
Cm		Kaibhen D.A., "The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthritis and its counteraction by a biological GAG-peptide complex (Rumalon®)", <u>Z. Rheumatol</u> (1982); 41: 202-211 F
Cm		Katsu M. et al., "Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence", <u>Nippon Rinsho</u> (1986 Jan) 26(1): 89-95 F + G
Cm		Kreis H et al, "Nonsteroid antiinflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients" <u>Transplantation</u> (1984 Feb); 37(2): 139-145 F
Cm		McIlwraith W, "Current concepts in equine degenerative joint disease", <u>Journal of the Am. Veterinary Medical Assoc.</u> 1982; Feb 1, vol. 180: 239-250 F
Cm		Mizushima Y., "Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future", <u>Nippon Rinsho</u> (Jan 1986); 26(1): 61-65 F
Cm		Nizolek D.J.H. et al, "Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A Review" <u>The Cornell Veterinarian</u> 1981; 71(4): 355-375 F
Cm		Pigman W et al, "Acide hyaluronique et facteurs de permeabilite tissulaire" <u>Bull. Soc. Chim. Biol.</u> 1963; 45(2-3): 185-202 F
Cm		Pruett RC, et al, "Hyaluronic acid vitreous substitute", In: <u>Vitreous Surgery and Advances in Fundus Diagnosis and Treatment</u> , H. McKenzie Freeman et al Editors, Appleton-Century-Crofts, 1977: Chapter 55, pp. 433-444 F
Cm		Reim M et al, "Surgical procedures in the treatment of most severe eye burns" <u>Acta Ophthalmologica</u> 1989-Supplementum 192; 67: 47-54 F

Examiner <i>C. Reda</i>	Date Considered <i>6666</i>
-------------------------	-----------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement by Applicant (Use several sheets if necessary)	ATTY. DOCKET NO. P-0800(O)-3	SERIAL NO. 08/462,147
	APPLICANT Hyal Pharmaceutical Corporation	
	FILING DATE June 5, 1995	GROUP 1211

OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

Examiner	<i>C. Pehle</i>	Date Considered	<i>6/6/96</i>
----------	-----------------	-----------------	---------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.